Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China

Abstract Background Delamanid (DLM) is a promising drug recommended for treatment of multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB). However, there are very little data about the emergence of drug resistance in patients with the use of DLM-containing regimens. The study aimed to monitor th...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Wei Shu, Qingshan Cai, Yuping Huang, Yuanhong Xu, Yuanyuan Shang, Ruixia Liang, Liang Yan, Lin Wang, Long Jin, Yi Pei, Zhongfeng Huang, Shanshan Li, Yufeng Wang, Mengqiu Gao, Liang Li, Yu Pang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2026-07-01
Rangatū:	Annals of Clinical Microbiology and Antimicrobials
Ngā marau:	Tuberculosis Delamanid resistance Multidrug-/Rifampicin-resistant
Urunga tuihono:	https://doi.org/10.1186/s12941-025-00820-9
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!